Owl Therapeutics, a wholly owned subsidiary of Gryphon Bio, entered into a global licensing and collaboration agreement with Swedish-based Abliva AB to advance Abliva’s NeuroSTAT (OWL-1410) for the prevention and treatment of moderate to severe traumatic brain injury (TBI).

Under the terms of the agreement, Abliva will contribute to both the operational and strategic elements of the program through the established steering committee. Owl Therapeutics will lead the clinical development and commercialization of NeuroSTAT. Upon commercialization, Abliva is eligible for royalties.

The collaboration agreement provides Owl Therapeutics with a global license to develop, manufacture, and commercialize NeuroSTAT.

“Abliva stands out as an exceptional partner for Owl Therapeutics, and we are excited to join forces in our collective commitment to advance NeuroSTAT (OWL-1410),” said William Haskins, co-Founder of Owl Therapeutics and CEO of Gryphon Bio. “We are thrilled to focus our team’s scientific, clinical, and business experience on this potentially game-changing treatment for military and civilian TBI patients.”

“Through this important collaboration with Abliva, Owl Therapeutics gains access to an innovative asset for TBI with orphan drug designation (ODD) in Europe and the U.S., as well as an investigational new drug (IND) approval granted Fast Track designation for clinical development and review in the U.S.,” said Franklin Okumu, chief technology officer of Owl Therapeutics. “We are also excited by the potential to collaborate with clinical investigators to rapidly advance this treatment to patients in need.”